Sandoz Group AG (SDZ.SW)
Sandoz Group AG operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Basel, CH. The stock last traded at $73.32, up 0.94% on the session, giving a market capitalisation of $31.73B. Its beta of 0.49 implies it has historically moved less than the broad market.
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
Sandoz Group AG is most often compared with the following Healthcare names: